Scarica l'app Stockscreener
14.21
5.36%
-0.805
Precedente Chiudi:
$15.02
Aprire:
$15.01
Volume 24 ore:
960.65K
Relative Volume:
0.90
Capitalizzazione di mercato:
$1.11B
Reddito:
$114.04M
Utile/perdita netta:
$-330.15M
Rapporto P/E:
-3.0042
EPS:
-4.73
Flusso di cassa netto:
$-274.85M
1 W Prestazione:
-10.23%
1M Prestazione:
-2.40%
6M Prestazione:
+54.79%
1 anno Prestazione:
+104.76%
Intervallo 1D:
$13.79
$15.01
Intervallo di 1 settimana:
$13.79
$18.09
Portata 52W:
$2.21
$18.31
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Nome
Phathom Pharmaceuticals Inc
Settore
Industria
Telefono
(877) 742-8466
Indirizzo
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Confronta PHAT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PHAT
Phathom Pharmaceuticals Inc
|
14.19 | 1.17B | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.87 | 117.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.69 | 83.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
780.75 | 48.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.88 | 52.62B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
334.61 | 37.39B | 4.98B | 69.59M | 525.67M | 0.5197 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | Raymond James | Strong Buy |
| 2025-12-09 | Iniziato | Barclays | Equal Weight |
| 2025-02-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Iniziato | Stifel | Buy |
| 2024-01-05 | Reiterato | Needham | Buy |
| 2023-08-09 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Iniziato | Craig Hallum | Buy |
| 2022-10-21 | Iniziato | Jefferies | Buy |
| 2022-05-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2021-02-17 | Iniziato | BMO Capital Markets | Outperform |
| 2021-02-02 | Iniziato | Guggenheim | Buy |
| 2020-06-26 | Downgrade | Goldman | Neutral → Sell |
| 2019-11-20 | Iniziato | Evercore ISI | Outperform |
| 2019-11-19 | Iniziato | Goldman | Neutral |
| 2019-11-19 | Iniziato | Jefferies | Buy |
| 2019-11-19 | Iniziato | Needham | Buy |
Mostra tutto
Phathom Pharmaceuticals Inc Borsa (PHAT) Ultime notizie
Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN
Should Phathom’s US$130 Million Equity Raise and Profitability Timeline Update Require Action From Phathom Pharmaceuticals (PHAT) Investors? - Yahoo Finance
Phathom: Why I’m Not Buying The Dip (Yet) (NASDAQ:PHAT) - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Phantom slumps 12%; prices $130M stock at $16 per share - MSN
Institution Moves: Can Phathom Pharmaceuticals Inc. stock hit analyst price targets2025 Market Trends & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability - Sahm
How Phathom Pharmaceuticals Inc. stock performs in stagflationJuly 2025 Update & Safe Investment Capital Preservation Plans - ulpravda.ru
Latham & Watkins Advises Phathom Pharmaceuticals on US$130 Million Public Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
Phathom Pharmaceuticals Announces $130 Million Public Offering - TipRanks
Form 424B5 Phathom Pharmaceuticals, - StreetInsider
Phathom Pharmaceuticals shares fall 13.1% after co announces $130 mln equity raise - marketscreener.com
Can Phathom Pharmaceuticals Inc. stock hit analyst price targetsTrade Performance Summary & Technical Entry and Exit Tips - ulpravda.ru
What's Going On With Phathom Pharma Stock Thursday?Phathom Pharmaceuticals (NASDAQ:PHAT) - Benzinga
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Drop— AZZ, Northrop Grumman, Immuneering In Focus (UPDATED) - Benzinga
Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Phathom Pharmaceuticals (PHAT) Benefits from Joint Book Running Managers - GuruFocus
Revenues Tell The Story For Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) As Its Stock Soars 27% - simplywall.st
Phathom Pharmaceuticals tumbles on $130 mln equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals prices $130 million public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals announces public offering of common stock By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals (PHAT) Launches $130M Public Offering - GuruFocus
Phathom Pharmaceuticals (PHAT) Stock Analysis: Unveiling a 26.66% Upside Potential Despite Negative Earnings - DirectorsTalk Interviews
Phathom Pharmaceuticals (PHAT) Prices Public Offering, Stock Dips - GuruFocus
Phathom (PHAT) Stock Pre-Market (-12%): Prices $130M Stock Offering at Discount - Trefis
Phathom Pharmaceuticals prices $130 million public offering - Investing.com
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Phathom Pharmaceuticals Announces Pricing of $130 Million - GlobeNewswire
Phathom Pharmaceuticals, Inc.Common Stock (NQ: PHAT - FinancialContent
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - TradingView — Track All Markets
Phathom Pharmaceuticals stock falls on planned public offering By Investing.com - Investing.com Nigeria
Phathom Pharmaceuticals drops after announcing planned equity raise - TradingView — Track All Markets
Phathom Pharmaceuticals announces public offering of common stock - Investing.com
PHAT Forecasts Profitable Operations by 2026 - GuruFocus
Phathom Pharmaceuticals stock falls on planned public offering - Investing.com
Phathom Pharmaceuticals files for mixed shelf offering size not disclosedSEC filing - MarketScreener
Phathom Pharma plans public offering after reporting preliminary 2025 results - MSN
Phathom Pharmaceuticals Reports Q4 Preliminary Revenue of $$57 Million to $58 Million - marketscreener.com
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Boston Herald - FinancialContent
Phathom Pharmaceuticals: Speculative Biotech Name Rides A Fresh Wave Of Volatility - AD HOC NEWS
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Phathom Pharmaceuticals grants RSUs and options to CEO Steven Basta | PHAT SEC FilingForm 4 - Stock Titan
(PHAT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Movement Recap: What makes Phathom Pharmaceuticals Inc stock attractive to growth funds2025 Big Picture & Real-Time Buy Signal Alerts - moha.gov.vn
Simplify Asset Management Inc. Reduces Position in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Hits New 52-Week HighHere's What Happened - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Is Expected To Breakeven In The Near Future - Yahoo Finance
Phathom Pharmaceuticals stock hits 52-week high at $17.87 By Investing.com - Investing.com South Africa
Phathom Pharmaceuticals stock hits 52-week high at $17.87 - Investing.com India
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Phathom Pharmaceuticals Inc Azioni (PHAT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Phathom Pharmaceuticals Inc Azioni (PHAT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Basta Steven L | President and CEO |
Nov 28 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
131,625 |
| Breedlove Robert Charles | Principal Accounting Officer |
Nov 03 '25 |
Sale |
13.51 |
524 |
7,079 |
47,407 |
| Basta Steven L | President and CEO |
Sep 25 '25 |
Option Exercise |
0.00 |
90,000 |
0 |
90,000 |
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
0.77%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):